Stock Analyst Predictions and Ratings for Colgate-Palmolive Shares
Grit Your Teeth Through Colgate's Rollercoaster Stock Performance
Jump on the Wall Street rollercoaster with our sassy Active Investor newsletter!
Get ready to bite into the thrilling world of Colgate-Palmolive Company (CL), a global behemoth in the oral care hygiene market. This toothsome titan churns out a smorgasbord of household, healthcare, and personal care products, boasting a mouthwatering market cap of a whopping $73.5 billion. Dive in as we dissect CL's Oral, Personal & Home Care, and Pet Nutrition segments!
Recently, CL has battled a bumpy ride on the stock market – alas, it's outpaced the competition in 2025, but trailed behind in the previous year. The stock's YTD performance saw a mere 10 bps uptick, and it slipped 2.3% over the 52 weeks, while the S&P 500 Index ($SPX) experienced a 4.7% plunge in 2025 and posted an 8.2% surge during the same period. Ouch!
Curious about what's lurking behind the scenes? Let's narrow our focus on CL's performance among industry peers. The oral hygiene giant fell short, lagging behind the Consumer Staples Select Sector SPDR Fund's (XLP) 3.5% gains on a YTD basis and 7.2% returns over the past year.
Fasten your seat belts – CL's stock prices surged 1.3% following the release of its Q1 results on Apr. 25. However, the champagne popped a bit too soon: the topline took a hit due to currency headwinds and reduced private label pet volume, with net sales for the quarter dropping 3.1% YoY to $4.9 billion. But this figure trumped the Street's estimates by an impressive 1.2%, while its adjusted EPS swelled 5.8% YoY to $0.91, blowing past consensus estimates by a significant margin. The ride took a U-turn the next trading day, as CL stock prices slid 3.1%.
Looking ahead, CL is expected to post a 1.4% YoY increase in adjusted EPS to $3.65 for fiscal 2025, ending in December. Don't let your guard down – the company has a stellar earnings surprise history, having surpassed Street estimates in each of the past four quarters.
The stock's overall rating is a "Moderate Buy," with various analyst opinions ranging from 11 "Strong Buys," two "Moderate Buys," seven "Holds," and two "Strong Sells." Citigroup (C) analyst Filippo Falorni recently maintained a "Buy" rating on CL, upping the price target from $103 to $108.
Planning your exit strategy? The average price target for CL is $99.14, with a high of $110 and a low of $86. The mean price target offers an 8.9% premium to current price levels, while the street-high target suggests a potential 20.9% upside.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view our Disclosure Policy here.
Insight: Colgate-Palmolive has displayed a resilient earnings surprise history over the past four quarters. Additionally, the company's Q1 2025 adjusted EBITDA surpassed analyst estimates by 3.9%.
- Despite Colgate-Palmolive Company's dominance in the oral care hygiene market with a staggering market cap of $73.5 billion, its stock performance has underperformed in the previous year, slipping 2.3%.
- In terms of investing, Colgate-Palmolive fell short compared to its industry peers, such as the Consumer Staples Select Sector SPDR Fund, which recorded 3.5% gains on a YTD basis and 7.2% returns over the past year.
- The oral hygiene giant, Colgate-Palmolive, shows a diverse business portfolio, not only in oral care products but also in nutrition, as evident in its Pet Nutrition segment.
- Technology analysts may find interest in the digital transformation initiatives undertaken by Colgate-Palmolive, as the company aims to improve its hygiene and nutrition offerings through advancements in technology.
